RARECast
A podcast by RARECast - Giovedì
548 Episodio
-
How One Drugmaker Reaches out to Communities at Greater Risk for Rare Heart Condition
Pubblicato: 03/03/2023 -
A Next-Generation RNA Therapy Targets Telomere Disorders
Pubblicato: 03/03/2023 -
BridgeBio Advances Therapy for Limb-Girdle Muscular Dystrophy that Started with Two Patient Families
Pubblicato: 24/02/2023 -
Translating Urgency into Science
Pubblicato: 16/02/2023 -
Empowering Ultra-Rare Disease Patients to Pursue the Discovery of Treatments
Pubblicato: 10/02/2023 -
Why a Topical Cannabidiol Gel May Help Treat the Behavioral Symptoms of Fragile X
Pubblicato: 02/02/2023 -
An Ultra-Rare Disease Drug Developer Tries to Navigate Regulatory Uncertainty
Pubblicato: 26/01/2023 -
Powering Cells in People with Rare Mitochondrial Diseases
Pubblicato: 19/01/2023 -
Powering Weakened and Stressed Cells in ALS to Function Better with Nanocrystal Therapy
Pubblicato: 12/01/2023 -
Developing a New Class of Therapies Based on a Natural Cargo Carrier
Pubblicato: 05/01/2023 -
Reaching Beyond the Limits of Enzyme Replacement Therapies with Gene Therapies
Pubblicato: 29/12/2022 -
One Woman’s Journey as a Caregiver to a Husband with Frontotemporal Dementia
Pubblicato: 22/12/2022 -
Treating Rare Endocrine Disorders with Therapeutic Peptides
Pubblicato: 15/12/2022 -
Tackling the Pricing Challenges for Advanced Therapies for Rare Diseases
Pubblicato: 08/12/2022 -
Addressing the Current Limitations of AAV Gene Therapies
Pubblicato: 01/12/2022 -
Examining the Legislative Landscape for Rare Disease Drug Development
Pubblicato: 24/11/2022 -
How a Drug Setback Became a Patient Community’s Gain
Pubblicato: 18/11/2022 -
Helping Regulators and Drug Developers Understand the Challenges of Living with Fabry Disease
Pubblicato: 10/11/2022 -
Addressing Racial Disparities in a Rare Blood Cancer
Pubblicato: 03/11/2022 -
How New Sequencing Technology Promises to Alter the Diagnostic Odyssey
Pubblicato: 27/10/2022
RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.